| scholarly article | Q13442814 |
| P50 | author | Pauline A van Schouwenburg | Q38322524 |
| P2093 | author name string | Michael T Nurmohamed | |
| Jos W R Twisk | |||
| Ben A C Dijkmans | |||
| Willem F Lems | |||
| Charlotte L M Krieckaert | |||
| Gerrit Jan Wolbink | |||
| Geertje M Bartelds | |||
| Lucien Aarden | |||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| adalimumab | Q348260 | ||
| P304 | page(s) | 1460-1468 | |
| P577 | publication date | 2011-04-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up | |
| P478 | volume | 305 |
| Q89733487 | 10th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals |
| Q90142674 | A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins |
| Q53523796 | A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease. |
| Q51041658 | A case of Crohn's disease that developed anti-infliximab and anti-adalimumab antibodies. |
| Q34496015 | A cholesterol-lowering VLP vaccine that targets PCSK9 |
| Q37484873 | A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice |
| Q35835741 | A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm |
| Q45020460 | A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. |
| Q37561560 | A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. |
| Q33731695 | A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab |
| Q50546879 | A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. |
| Q47247174 | A survey of applications of biological products for drug interference of immunogenicity assays |
| Q38082233 | Active immunotherapy for chronic diseases |
| Q43510384 | Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease |
| Q46877467 | Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells |
| Q34669637 | Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation |
| Q42289113 | Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database |
| Q57292102 | Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up |
| Q35614190 | Advances in phage display technology for drug discovery |
| Q38238948 | Adverse reactions to biologic agents and their medical management. |
| Q37708477 | Allergic sensitization: screening methods. |
| Q28553954 | Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study |
| Q38323592 | Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease |
| Q37965581 | Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use? |
| Q38063585 | Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine |
| Q89462107 | Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial |
| Q45911203 | Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases. |
| Q37517101 | Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence |
| Q38152820 | Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response |
| Q38916583 | Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab |
| Q49996897 | Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time |
| Q39019308 | Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial |
| Q41248107 | Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study. |
| Q35557970 | Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases |
| Q57265316 | Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient |
| Q44805804 | Antibody response against Betaferon® in immune tolerant mice: involvement of marginal zone B-cells and CD4+ T-cells and apparent lack of immunological memory |
| Q28082303 | Antidrug Antibodies: B Cell Immunity Against Therapy |
| Q41315257 | Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins |
| Q38151757 | Antidrug antibodies in psoriasis: a systematic review |
| Q91993165 | Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice |
| Q39022950 | Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development. |
| Q43013714 | Are we ready for therapeutic drug monitoring of biologic therapeutics? |
| Q38083093 | Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations |
| Q26751485 | Assessing the Immunogenicity of Biopharmaceuticals |
| Q33804009 | Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations |
| Q53813065 | Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease. |
| Q51076666 | Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects. |
| Q38568898 | Biologic agents for IBD: practical insights |
| Q26783657 | Biologic efficacy optimization--a step towards personalized medicine |
| Q38123192 | Biologic fatigue in psoriasis. |
| Q38643965 | Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events. |
| Q40045451 | Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries |
| Q39271088 | Biomaterial strategies for generating therapeutic immune responses |
| Q49979586 | Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review |
| Q37080199 | Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. |
| Q60044823 | Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study |
| Q38093772 | Challenges and approaches for the development of safer immunomodulatory biologics |
| Q30847784 | Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors |
| Q28535018 | Cholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragments |
| Q38702792 | Clinical Decision Support Tools: The Evolution of a Revolution |
| Q36819607 | Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn's disease patients |
| Q38364465 | Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety |
| Q36272813 | Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results |
| Q38212907 | Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies |
| Q48370561 | Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis |
| Q50517177 | Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. |
| Q45083749 | Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. |
| Q36832755 | Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis |
| Q39420995 | Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review. |
| Q44656935 | Comment on 'Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study'. |
| Q45578783 | Comment on 'Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study': reply from authors |
| Q39542719 | Comparable outcomes of the consistent use versus switched use of anti- tumor necrosis factor agents in postoperative recurrent Crohn's disease following ileocolonic resection |
| Q42734907 | Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System |
| Q36472687 | Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry |
| Q37452967 | Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study |
| Q92404019 | Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis |
| Q50867897 | Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease. |
| Q38291910 | Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices |
| Q50073706 | Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases |
| Q34211985 | Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population |
| Q37992954 | Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis |
| Q36776326 | Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers |
| Q36214720 | Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity |
| Q46355891 | Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti-TNF-α Antibodies after a Single Injection in Mice |
| Q39278646 | Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD. |
| Q38133655 | Current immunotherapy in rheumatoid arthritis |
| Q36057909 | Current status and future prospects for biologic treatments of psoriasis |
| Q37952792 | Cytokine blockade in inflammatory bowel diseases |
| Q40741730 | Defining medication adherence in individual patients |
| Q38898145 | Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits |
| Q48060378 | Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations. |
| Q51158618 | Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay. |
| Q37383419 | Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. |
| Q35309576 | Detection of autoantibodies in a point-of-care rheumatology setting |
| Q50536154 | Determination of adalimumab and etanercept trough levels and drug antibodies in long-term psoriasis treatment: a single-centre cohort study. |
| Q47308760 | Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study |
| Q47687442 | Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature. |
| Q47974635 | Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases |
| Q44616013 | Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases |
| Q50083992 | Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. |
| Q35048347 | Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab |
| Q53366166 | Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up. |
| Q37599165 | Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. |
| Q53761469 | EXXELERATE: a negative trial with importance for clinical practice. |
| Q37283495 | Editor's Highlight: Subvisible Aggregates of Immunogenic Proteins Promote a Th1-Type Response. |
| Q26739150 | Effect of Anti-TNF Antibodies on Clinical Response in Rheumatoid Arthritis Patients: A Meta-Analysis |
| Q46131525 | Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register |
| Q50224633 | Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors |
| Q38203622 | Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis |
| Q35660768 | Emerging patient safety issues under health care reform: follow-on biologics and immunogenicity |
| Q41561618 | Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab. |
| Q54013327 | Etanercept, Adalimumab und Ustekinumab bei Psoriasis: Analyse von 209 Behandlungsreihen in Österreich. |
| Q38940190 | Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria |
| Q36653930 | Evaluating and Reporting the Immunogenicity Impacts for Biological Products--a Clinical Pharmacology Perspective |
| Q64106814 | Evaluation of Assays to Assess the Modulation of Dendritic Cells Functions by Therapeutic Antibodies and Aggregates |
| Q92327988 | Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet's disease-related uveitis |
| Q30725001 | Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry |
| Q38202541 | Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies |
| Q38261166 | Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies |
| Q86421510 | Gammaglobulins, autoantibodies, therapeutic antibodies and anti-drug antibodies in rheumatoid arthritis |
| Q37604498 | High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort |
| Q64927637 | How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy. |
| Q61640354 | IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients |
| Q50065301 | Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab |
| Q28554222 | Immunogenicity and Lupus-Like Autoantibody Production Can Be Linked to Each Other along With Type I Interferon Production in Patients with Rheumatoid Arthritis Treated With Infliximab: A Retrospective Study of a Single Center Cohort |
| Q47855368 | Immunogenicity assessment during the development of protein therapeutics |
| Q26865822 | Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection |
| Q39371316 | Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review |
| Q90836400 | Immunogenicity of Protein Pharmaceuticals |
| Q38080683 | Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis |
| Q38150903 | Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue? |
| Q26798357 | Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice |
| Q38473460 | Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate |
| Q26827399 | Immunogenicity of biotherapy used in psoriasis: the science behind the scenes |
| Q36411853 | Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice |
| Q38631012 | Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? |
| Q30390955 | Immunogenicity of mAbs in non-human primates during nonclinical safety assessment |
| Q48238341 | Immunogenicity of protein aggregates of a monoclonal antibody generated by forced shaking stress with siliconized and nonsiliconized syringes in BALB/c mice. |
| Q37207756 | Immunogenicity of subcutaneously administered therapeutic proteins--a mechanistic perspective |
| Q26766424 | Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes |
| Q35888359 | Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy |
| Q46104161 | Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up |
| Q42674160 | Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study |
| Q45911665 | Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results. |
| Q35547487 | Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients |
| Q90975379 | Impact of human sequences in variable domains of therapeutic antibodies on the location of CD4 T-cell epitopes |
| Q38920322 | Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study |
| Q31090015 | Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses |
| Q37719806 | Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease |
| Q51602149 | Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles. |
| Q89850099 | In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA: An Encouraging Milestone to Further Clinical Drug Development |
| Q30235581 | Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview. |
| Q28551216 | Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study |
| Q35592110 | Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients |
| Q50745427 | Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. |
| Q53809586 | Interleukin 17-A inhibition in the treatment of psoriasis. |
| Q91868669 | Introducing Patterns of Variability for Overcoming Compensatory Adaptation of the Immune System to Immunomodulatory Agents: A Novel Method for Improving Clinical Response to Anti-TNF Therapies |
| Q36575283 | Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis? |
| Q39042940 | Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis? |
| Q26766368 | Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example |
| Q54459547 | Key findings towards optimising adalimumab treatment: the concentration-effect curve. |
| Q55259703 | Label-Free Quantification of Anti-TNF-α in Patients Treated with Adalimumab Using an Optical Biosensor. |
| Q47109031 | Local retention of antibodies in vivo with an injectable film embedded with a fluorogen-activating protein |
| Q37338261 | Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers |
| Q42640551 | Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. |
| Q30811550 | Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment |
| Q60046431 | Low Percentage of Signal Regulatory Protein α/β Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients |
| Q34420269 | Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. |
| Q33408915 | Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study |
| Q38916421 | Management of Juvenile Idiopathic Arthritis: A Clinical Guide |
| Q26786213 | Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis |
| Q92771579 | Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial |
| Q90043746 | Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue |
| Q61796098 | Modulation of Intestinal Epithelial Permeability by Plasma from Patients with Crohn's Disease in a Three-dimensional Cell Culture Model |
| Q40624064 | Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment |
| Q38828876 | Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis |
| Q45174752 | Moving towards a new class of vaccines for non-infectious chronic diseases |
| Q99711516 | Multifactorial Design of a Supramolecular Peptide Anti-IL-17 Vaccine Toward the Treatment of Psoriasis |
| Q28073763 | New pharmacological strategies in rheumatic diseases |
| Q42622733 | No Correlations Between the Development of Specific IgA and IgM Antibodies Against Anti-TNF Blocking Agents, Disease Activity and Adverse Side Reactions in Patients with Rheumatoid Arthritis |
| Q38673326 | Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences |
| Q26827714 | Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy |
| Q92976912 | Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform |
| Q38822920 | Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. |
| Q37620900 | Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial |
| Q91652147 | Peptide-Based Vaccination Therapy for Rheumatic Diseases |
| Q43788885 | Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects |
| Q38084444 | Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine |
| Q35023731 | Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis |
| Q85478139 | Pharmacokinetics of adalimumab in Crohn's disease |
| Q38831148 | Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins |
| Q47918450 | Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis |
| Q26784434 | Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials |
| Q44750379 | Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis |
| Q48092457 | Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching |
| Q38628770 | Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease |
| Q87851441 | Practical application of acid dissociation in monitoring patients treated with adalimumab |
| Q42373188 | Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. |
| Q28547255 | Predicting Hemagglutinin MHC-II Ligand Analogues in Anti-TNFα Biologics: Implications for Immunogenicity of Pharmaceutical Proteins |
| Q38095548 | Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. |
| Q51046105 | Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement. |
| Q41015565 | Predictive Value of Serum Infliximab Levels at Induction Phase in Rheumatoid Arthritis Patients |
| Q28546596 | Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis |
| Q49161489 | Pro-inflammatory cytokines and leukocyte oxidative burst in chronic kidney disease: culprits or innocent bystanders? |
| Q39453656 | Protection from articular damage by passive or active anti-tumour necrosis factor (TNF)-α immunotherapy in human TNF-α transgenic mice depends on anti-TNF-α antibody levels |
| Q46172380 | Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. |
| Q35544546 | Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study |
| Q36754078 | Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks |
| Q37944433 | Safety of biologic therapy in rheumatoid arthritis |
| Q38678882 | Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice |
| Q48247861 | Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors. |
| Q40791552 | Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment |
| Q52608304 | Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review. |
| Q51627957 | Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study. |
| Q92869667 | Shifting Paradigms Revisited: Biotechnology and the Pharmaceutical Sciences |
| Q47138621 | Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial. |
| Q47107623 | Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment |
| Q64913856 | Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy. |
| Q27009385 | Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium |
| Q38232124 | Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact |
| Q42343328 | Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature |
| Q51486721 | Surface plasmon resonance-based methodology for anti-adalimumab antibody identification and kinetic characterization. |
| Q45869248 | Sustained secretion of anti-tumor necrosis factor α monoclonal antibody from ex vivo genetically engineered dermal tissue demonstrates therapeutic activity in mouse model of rheumatoid arthritis |
| Q50034734 | Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: 52-Week Phase 3 Randomized Study Results |
| Q35686285 | Systemic adalimumab induces peripheral corneal infiltrates: a case report |
| Q38206507 | TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease |
| Q38097327 | TNF inhibition for ophthalmic indications: current status and outlook |
| Q38323786 | Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications. |
| Q50931633 | The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. |
| Q35840998 | The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab |
| Q38222900 | The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences |
| Q38033127 | The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what's in it for African and Middle Eastern rheumatologists |
| Q45749970 | The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure |
| Q33610284 | The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study |
| Q40206740 | The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. |
| Q50935053 | The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab. |
| Q89868138 | The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis |
| Q38129037 | The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. |
| Q37301134 | The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents |
| Q38755133 | The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis |
| Q38826447 | Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link. |
| Q41482221 | Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease |
| Q38160305 | Therapeutic drug monitoring in rheumatic diseases: utile or futile? |
| Q37948705 | Therapeutic drug monitoring of biologics for inflammatory bowel disease |
| Q38564877 | Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology |
| Q91819492 | Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis |
| Q38238931 | Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides |
| Q60308037 | Tofacitinib for refractory uveitis and scleritis |
| Q58779800 | Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology |
| Q53369582 | Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany. |
| Q91810091 | Understanding Inter-Individual Variability in Monoclonal Antibody Disposition |
| Q52318963 | Understanding the In Vivo Fate of Radioimmunoconjugates for PET and SPECT. |
| Q26747193 | Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance |
| Q38243891 | Unnatural amino acids in novel antibody conjugates |
| Q88601409 | Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia? |
| Q89399148 | Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum |
| Q92132694 | What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis? |
| Q46057173 | What is ascertained in the therapy of axial spondyloarthritis? |
| Q30826279 | What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort |
| Q44812839 | What to take from TREAT? |
| Q38027571 | When is switching warranted among biologic therapies in rheumatoid arthritis? |
| Q51641849 | Whole genome analysis on the genetic backgrounds associated with the secondary failure to etanercept in patients with rheumatoid arthritis. |
| Q84027466 | [Anti-drug antibodies, auto-antibodies and biotherapy in psoriasis] |
| Q84509549 | [Biologicals 2012] |
| Q83144497 | [What's new in dermatological therapy?] |
Search more.